The National Institute of Allergy and Infectious Diseases (NIAID) intends to negotiate, under the authority of 41 USC 253(c)(1) and FAR 6.302-1, a modification to its Indefinite Delivery/Indefinite Quantity seven (7) year pool of contracts including: N01-AI-95366, Advanced BioScience Laboratories, Inc.; N01-AI-95367, Chiron Corporation; N01-AI-95368, Immune Response Corporation; N01-AI-95369, Progenics Pharmaceuticals; N01-AI-95370, Protein Sciences Corporation; N01-AI-95371, Therion Biologics; N01-AI-95373, VaxGen Incorporated; N01-AI-95374, Vical. Inc.; N01-AI-95375, SRI International; N01-AI-95376, Vical, Inc.; N01-AI-95377, Progenics Pharmaceuticals; N01-AI-95378, Therion Biologics Corporation; N01-AI-95379, SRI International; N01-AI-15424, Chiron Corporation; N01-AI-15425, TherImmune Research Corporation; N01-AI-15426, Spring Valley Laboratories, Inc.; N01-AI-15427, Science Applications International Corporation (SAIC); N01-AI-15428, EER Systems, Inc.; and N01-AI-25473, Chiron Corporation. These contracts currently provide for HIV Vaccine Production, Preclinical Testing, and FDA Submissions. The modification will expand the capacity to include other NIAID Category A, B, and C priority pathogens. Inherent duplication of cost to the Government and unacceptable delays make competition unfeasible for the remaining four years of this IDIQ pool. See Numbered Note 22.

Bid Protests Not Available